Photo via Fast Company
A controversial sports competition launching this Memorial Day weekend is upending traditional athletic standards by explicitly permitting performance-enhancing drugs. According to Fast Company, the Enhanced Games—organized by a publicly traded longevity medicine company—will feature 42 elite athletes, including Olympic medalists, competing in swimming, weightlifting, and running events with approximately $25 million in prize money at stake.
The event reflects a growing market opportunity in the direct-to-consumer wellness sector. Enhanced, which recently went public in May, has secured backing from high-profile investors including Donald Trump Jr.'s 1789 Capital and entrepreneur Peter Thiel. The company positions itself as a 'longevity medicine' provider, though the competition itself has drawn sharp criticism from the International Olympic Committee and World Anti-Doping Agency for legitimizing substances banned in traditional sports.
While the games operate outside standard athletic regulations, organizers have implemented guardrails: participating athletes may only use FDA-approved substances, including human growth hormones, testosterone variants, and metabolic modulators. Some competitors receive monthly stipends alongside coaching, medical oversight, and nutritional support through Enhanced's Performance Team—a model that blurs lines between sports sponsorship and pharmaceutical promotion.
The venture highlights evolving attitudes toward performance optimization in competitive athletics and raises questions for healthcare professionals and business leaders about regulatory oversight. As the wellness and longevity medicine markets expand—peptides alone have surged in popularity this year—stakeholders must grapple with how traditional safeguards apply to emerging business models that commodify human performance enhancement.
